TMFBiologyFool

Article

TMFBiologyFool published an article 3:42 PM

Merck Stock Is a Good Investment (According to Merck)

Merck accelerates its buyback.

Article

TMFBiologyFool published an article 3:41 PM

MannKind's Run to Glory

But where will this stock's run end?

Article

TMFBiologyFool published an article 3:49 PM

The Surprising Link Between ADHD and Obesity

This disorder in childhood could put your adult health at risk.

Article

TMFBiologyFool published an article 4:06 PM

Biotech Companies: The FDA Doesn't Care About Your Phase 3 Trials

Results? Yes. Starting them? Not so much.

Article

TMFBiologyFool published an article 11:00 AM

Pick Your Poison: Overweight or High Cholesterol

Researchers discover that cholesterol-lowering Zocor hindered positive effects of exercise for obese and overweight adults.

Article

TMFBiologyFool published an article 7:10 PM

Cancer Meeting Highlights the Good and Bad of the Immune System

The immune system can kill tumors, but it can also go haywire.

Article

TMFBiologyFool published an article 7:03 PM

Weight Loss Isn't Just for Looking Good Anymore

Medical benefits are helping obesity drugs get coverage. Will the government help?

Article

TMFBiologyFool published an article 6:35 PM

Racing Toward the Next Hepatitis C Drug Approval

Johnson & Johnson jumps ahead of Gilead Sciences in the race to bring next-generation hepatitis C drugs to market.

Article

TMFBiologyFool published an article 3:56 PM

Diversifying Royalties at a Hefty Cost

Elan buys 21% of Thervance's royalties on Glaxo's lung drugs.

Article

TMFBiologyFool published an article 11:00 AM

Some Fish Oil Doesn't Help Some Patients in Some Countries

Be careful reading too much into the recently published clinical trial.

Article

TMFBiologyFool published an article 5:08 PM

The First Step in Treating Type 2 Diabetes

Metformin has become doctor's go-to drug.

Article

TMFBiologyFool published an article 2:13 PM

No Fat in This Drug Launch

Amarin releases sales for the first quarter that Vascepa was on the market.

Article

TMFBiologyFool published an article 2:16 PM

This Biotech Is Looking for a Fourth-Quarter Comeback

After a crummy quarter, Dendreon looks to ramp up sales

Article

TMFBiologyFool published an article 6:31 PM

Obesity Drug Demand Still Low

VIVUS manages just $4.1 million in sales of Qsymia.

Article

TMFBiologyFool published an article 1:43 PM

The Long Wait for This Obesity Drug Is Almost Over

The DEA issues its final ruling on Belviq, the last step before launch.

Article

TMFBiologyFool published an article 2:50 PM

Looking For Real Viagra? Head to the Internet.

Pfizer starts selling Viagra via its website.

Article

TMFBiologyFool published an article 8:00 AM

U.S.-Approved Obesity Drug Derailed in EU

Arena Pharmaceuticals and Eisai withdraw their application for obesity drug Belviq.

Article

TMFBiologyFool published an article 6:33 PM

FDA Approves Powerful New Cholesterol Drug

Merck's Liptruzet is a combination of Lipitor and Zetia.

Article

TMFBiologyFool published an article 10:56 PM

Shorter Treatments for Hepatitis C Patients on Their Way

Gilead demonstrates that its drug combination works in as little as eight weeks.

Article

TMFBiologyFool published an article 10:12 PM

Merck Stock Down, Could Have Been Worse

Despite a disastrous quarter, shares only fell 3%, probably because of a share repurchase program.